Novoseven (Eptacog Alfa (Activated))

Eptacog alfa, the active ingredient in Novoseven, is a recombinant activated factor VII presented as an injectable solution for intravenous use. It is employed to control bleeding in patients with hemophilia who have inhibitors and in other severe hemorrhagic situations.

GNH USA supplies Novoseven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Novoseven is a recombinant activated factor VII used in the management of bleeding disorders and acute hemorrhage. - Hemophilia A or B with inhibitors: rapid control of spontaneous or traumatic bleeding episodes. - Acquired hemophilia: cessation of bleeding when factor VIII inhibitors are present. - Severe trauma or uncontrolled surgical bleeding: hemostasis when conventional therapy is ineffective. - Peri‑operative bleeding in hemophilia patients with inhibitors: prevention of excessive intra‑operative blood loss.

Novoseven may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema - Fever or chills - Headache - Nausea - Hypotension - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Thromboembolic events (e.g., deep vein thrombosis, stroke) - Disseminated intravascular coagulation - Severe allergic reactions, including anaphylaxis - Acute respiratory distress syndrome - Cardiac arrest - Severe hypotension requiring intervention

Novoseven should be used with careful clinical assessment and monitoring. - Bleeding risk assessment: evaluate underlying coagulopathy before administration. - Thrombotic risk: monitor patients with a history of thrombosis or cardiovascular disease. - Pregnancy and lactation: limited data; use only if benefits outweigh risks. - Renal or hepatic impairment: consider dose adjustment and close observation. - Concomitant anticoagulants or pro‑coagulants: assess for additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novoseven may interact with other agents affecting coagulation.

Major Interactions (Avoid): - Concurrent use of other pro‑coagulant agents (e.g., activated prothrombin complex concentrates) may increase risk of thrombosis. - High‑dose antifibrinolytics combined with Novoseven can precipitate thrombotic complications.

Moderate Interactions (Monitor Closely): - Anticoagulants such as heparin or direct oral anticoagulants may reduce efficacy; monitor coagulation parameters. - Vitamin K antagonists: adjust therapy based on INR and clinical response. - Certain antibiotics (e.g., aminoglycosides) may interfere with clotting factor activity; observe for altered hemostasis.